|Karo Pharma AB -- USA Stock|| |
USD 4.10 4.10 9,223,372,036,855%
Chairman of the Board
Mr. Anders Lonner was Executive Chairman of the Board of Directors of Karo Pharma AB since February 4, 2015. He has previously been Independent Chairman of the Board since May 8, 2014. He holds MS in Political Science degree. He was previously Chief Executive Officer and President for Meda AB and had before then been CEO for Astra Lakemedel with responsibility for, among other things, Astras Nordic subsidiaries, CEO in Karo Bio AB and President of Lakemedelsforeningen. He is Advisor for EQT. In 2014 he was nominated Honorary Doctor of Medicine at Karolinska Institutet.
Age: 72 Chairman Since 2015
46 86 08 60 00 http://www.karobio.com
The company has return on total asset (ROA)
of 4.14 %
which means that it generated profit of $4.14 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE)
of 16.6 %
meaning that it generated $16.6 on every $100 dollars invested by stockholders.
The company has accumulated 77.45 M in total debt with debt to equity ratio (D/E) of 58.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Karo Pharma AB has Current Ratio of 2.06 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Karo Pharma AB , a pharmaceutical company, develops various drugs in Sweden. Karo Pharma AB (KARBF) is traded on OTC Market in USA. It is located in Stockholm, and employs 39 people.